Pterygium
Drug research and approvals for pterygium: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 6 studies of pterygium are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 6
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the EyeNCT07634913 · Not reported · Zhongshan Ophthalmic Center, Sun Yat-sen University · starts Dec 12, 2023
- Conjunctival Transpositional Surgery for Primary PterygiumNCT07343011 · Not applicable · Zahedan University of Medical Sciences · starts May 21, 2025
- Comparison of Compressed Continuous Suture and Conventional Suture in Pterygium SurgeryNCT07244276 · Not applicable · Tianjin Eye Hospital · starts Apr 2, 2024
- Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural CellsNCT06967831 · Not reported · Charite University, Berlin, Germany · starts Mar 1, 2020
- HoFH, the International Clinical Collaborators RegistryNCT04815005 · Not reported · University of Pennsylvania · starts Jan 24, 2017
- Cauterization Versus fibrin Glue for Conjunctival Autografting in Primary Pterygium SurgeryNCT03321201 · Not applicable · University of Split, School of Medicine · starts May 8, 2018
Phase 3 7
- BevacizumabVascular endothelial growth factor A inhibitor
- HistamineHistamine H1 receptor agonist
- AntazolineHistamine H1 receptor antagonist
- NaphazolineAdrenergic receptor alpha agonist
- TetrahydrozolineAdrenergic receptor alpha agonist
- Fibrin
- Tranilast
Phase 2 3
- RanibizumabVascular endothelial growth factor A inhibitor
- MitomycinDNA inhibitor
- CyclosporineCyclophilin A modulator
How its trials ended
102 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 15 whose ending is known, 53% met their primary endpoint, 20% missed it and 27% stopped early.
- Completed, result not reported4746%
- Status unknown3231%
- Met its primary endpoint88%
- Ongoing88%
- Missed its primary endpoint33%
- Stopped: other or unclear22%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jan 13, 2011 | MitomycinPrevention of recurrence of pterygium after its surgical excision. | Glaukos Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA